FDA Clarifies Regulatory Expectations for Digital Tools Claiming Stress Reduction and Sleep Improvement

FDA Guidance Clarifies Boundaries for Oversight of Digital Tools for Stress and Sleep

The FDA applies regulatory oversight to digital health technologies only when those products meet the statutory definition of a medical device and are intended to diagnose, treat, mitigate or prevent disease. Low-risk general wellness products that help users manage stress, improve sleep or maintain a healthy lifestyle without specific disease claims fall outside that oversight. The agency first described its enforcement approach in 2016 guidance and later created the Digital Health Center of Excellence to coordinate policy on software, wearables and mobile apps.

Sleep problems remain widespread among adults. CDC figures underscore the public health context for consumer interest in these tools. [3]

General Wellness Tools Fall Outside Device Oversight

The FDA does not intend to examine low-risk general wellness products. These include technologies intended to promote physical fitness, encourage healthy eating, manage stress, or improve sleep without disease claims. [1]

The policy has guided agency decisions since its 2016 release.

Enforcement Discretion Applies to Many Consumer Apps

Mobile apps used solely for maintaining or encouraging a healthy lifestyle are not medical devices. The FDA applies enforcement discretion to wellness apps that do not claim to diagnose, treat, mitigate, or prevent conditions such as insomnia, anxiety disorders, or sleep apnea. [1]

This approach covers many popular sleep trackers and stress biofeedback tools available to consumers today. The agency focuses its resources on higher-risk products instead.

Digital Health Center Coordinates Oversight Strategy

The FDA established its Digital Health Center of Excellence in 2022. The center coordinates regulatory approaches for software, wearables, and mobile apps that track sleep and stress among other functions. [2]

Its work supports consistent policy application across the agency.

Claims Determine Regulatory Status

Intended use and specific claims decide whether a product requires FDA review. The technology platform itself does not trigger oversight. A wearable that simply reports sleep duration stays in the wellness lane. One that asserts it treats clinical insomnia crosses into medical device territory. [1]

Developers compare their labeling and promotional materials against the agency's examples.

What this means

The FDA's framework allows many stress and sleep tools to reach the market without premarket clearance. It places weight on whether claims stay general rather than disease-specific. At the same time, the policy leaves questions of clinical effectiveness and long-term user outcomes outside the agency's review for these low-risk products. Public health data from the CDC continue to highlight widespread sleep concerns that these tools aim to address, yet the guidance itself does not evaluate performance. [3]

Key takeaways

• Low-risk DHTs focused on general wellness for stress reduction or sleep improvement are outside FDA medical device oversight. [1]
• Intended use and specific claims determine regulatory status rather than the technology platform itself. [1]
• The FDA applies enforcement discretion to many consumer wellness apps and wearables. [2]
• Higher-risk claims (e.g., treating clinical insomnia) trigger device classification and potential premarket requirements. [1]
• Guidance documents are not binding law and remain subject to revision. [2]

Limitations

Guidance documents are not binding law and remain subject to public comment or revision. They do not address data privacy, cybersecurity vulnerabilities, or requirements for clinical evidence of effectiveness. Independent validation studies on long-term outcomes of consumer DHTs remain limited.

FAQ

When does a stress or sleep app or wearable qualify as an FDA-regulated medical device?
It qualifies when its intended use involves diagnosing, treating, mitigating, or preventing disease or specific conditions such as insomnia or anxiety disorders.

What is the difference between general wellness claims and medical claims under FDA policy?
General wellness claims focus on supporting healthy lifestyle choices without reference to disease. Medical claims assert an ability to diagnose or treat conditions and trigger device classification. [1]

How do developers determine if their digital health technology requires premarket review?
Developers examine the product's intended use and all promotional claims against FDA examples in its general wellness guidance. Claims that stay within low-risk wellness boundaries typically avoid premarket requirements.

What role does the Digital Health Center of Excellence play in DHT oversight?
The center coordinates regulatory policy for digital health technologies across the FDA. It supports consistent approaches to software, wearables, and apps including those used for sleep and stress tracking. [2]